Stemtech Q2 FY26 net loss narrows 1.32% to $292,358; net sales fall 9.8% to $629,312
Reuters2026/08/14 20:49- Stemtech posted a net loss of USD 292,358 for Q2 ended June 30, 2026, narrowing from USD 296,280 a year earlier.
- Net sales fell 9.8% to USD 629,312 on constrained product availability across key lines that limited distributor order fulfillment.
- Operating loss narrowed to USD 125,567 from USD 300,988 as operating expenses dropped to USD 591,240 from USD 853,004.
- Gross margin slid 5.1 percentage points to 74% as mix worsened, with fixed fulfillment and freight costs weighing.
- February launch of the Stemtech BioSciences e-commerce platform targets broader retail distribution and greater direct consumer access.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UBS lowers Ciena target price to $394
EUR/USD Price Forecast: Holds key 100-day SMA at start of the US CPI week
Malaysia Govt Spending Plan Could Help 99 Speed Mart Retail -- Market Talk
Paying the price for supporting the yen? Japan's foreign reserves fell by $87.8 billions in August, possibly due to selling US Treasuries for funding.
Japanese authorities may have used part of their foreign exchange reserves, including foreign securities such as U.S. Treasury bonds, over the past month to fund record-sized foreign exchange intervention operations.
Crypto prices
More
